Efficient Delivery of Therapeutic siRNA by Fe₃O₄ Magnetic Nanoparticles into Oral Cancer Cells

• Asıl Yazarlar: Lili Jin (Yazar), Qiuyu Wang (Yazar), Jiayu Chen (Yazar), Zixiang Wang (Yazar), Hongchuan Xin (Yazar), Dianbao Zhang (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2019-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.
• Notes: 1999-4923; 10.3390/pharmaceutics11110615
• Keywords: magnetic nanoparticle; iron oxide; sirna delivery; bcl2; birc5/survivin; oral cancer; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 11, Iss 11, p 615 (2019)

The incidence of oral cancer is increasing due to smoking, drinking, and human papillomavirus (HPV) infection, while the current treatments are not satisfactory. Small interfering RNA (siRNA)-based therapy has brought hope, but an efficient delivery system is still needed. Here, polyethyleneimine (PEI)-modified magnetic Fe₃O₄ nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. The cationic nanoparticles were characterized by transmission electronic microscopy (TEM), scanning electronic microscopy (SEM), dynamic light scattering (DLS), and vibrating sample magnetometer (VSM). By gel retardation assay, the nanoparticles were found to block siRNA in a concentration-dependent manner. The cellular uptake of the nanoparticle/siRNA complexes under a magnetic field was visualized by Perl’s Prussian blue staining and FAM labeling. High gene silencing efficiencies were determined by quantitative real-time PCR and western blotting. Furthermore, the nanoparticle-delivered siRNAs targeting BCL2 and BIRC5 were found to remarkably inhibit the viability and migration of Ca9-22 cells, by cell counting kit-8 assay and transwell assay. In this study, we have developed a novel siRNA-based therapeutic strategy targeting BCL2 and BIRC5 for oral cancer.